
GSK's Arexvy Vaccine Shows Strong Efficacy Against RSV in Older Adults
The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract disease in older adults over 3 seasons.
This article was originally published on
GSK has announced promising results for Arexvy, its
The findings were presented at the
GSK plans to continue providing long-term efficacy and immune response data to help inform revaccination schedules. RSV impacts an estimated 64 million people globally each year and can lead to severe outcomes, causing over 465,000 hospitalizations and 33,000 deaths annually among adults aged 60 and older in high-income countries.
“We are excited by these new data which show that a single dose of Arexvy could help protect millions of older adults at risk of RSV disease over three seasons to benefit public health," Tony Wood, chief scientific officer at GSK, said in a statement. "This is the only RSV vaccine with efficacy and safety data available through 3 full seasons. We will continue to provide data on longer term follow-up to help recommending bodies determine future revaccination schedules.”
Arexvy was approved by the FDA in May 2023 for preventing RSV-LRTD in individuals aged 60 and older. Since then, it has received approvals in 50 countries, including Europe and Japan.
The ongoing research aims to provide further insights into the vaccine's long-term effectiveness and the necessity for potential revaccination.
References
- GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons. GSK. October 8, 2024. Accessed October 21, 2024.
https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-for-arexvy-its-rsv-vaccine-indicating-protection-over-three-rsv-seasons/ - Cosdon, N. FDA approves GSK’s Arexvy as the world’s first RSV vaccine for older adults. Contagion. May 3, 2024. Accessed October 21, 2024.
https://www.contagionlive.com/view/fda-approves-gsk-s-arexvy-as-the-world-s-first-rsv-vaccine-for-older-adults
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.